Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

doi:10.1200/JCO.2010.34.1578

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Aug 2011

Oza Amit M, Elit Laurie, Tsao Ming-Sound, Kamel-Reid Suzanne, Biagi Jim, Provencher Diane Michele, Gotlieb Walter H, Hoskins Paul J, Ghatage Prafull, Tonkin Katia S, Mackay Helen J, Mazurka John, Sederias Joana, Ivy Percy, Dancey Janet E, Eisenhauer Elizabeth A

Abstract excerpt

PURPOSE: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Endometrial Neoplasms

Share to Neoplasm Metastasis

Share to Recurrence

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 21788564
DOI: 10.1200/JCO.2010.34.1578
PMCID: PMC3158598

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.PMID 21788564Read ↗

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Semantic proximity Read ↗

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.Semantic proximity Read ↗

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.Semantic proximity Read ↗

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.Semantic proximity Read ↗

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.Semantic proximity Read ↗

MicroRNA-199a-3p Regulates Endometrial Cancer Cell Proliferation by Targeting Mammalian Target of Rapamycin (mTOR)Semantic proximity Read ↗

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.Semantic proximity Read ↗

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.Semantic proximity Read ↗

Phase II trial of temsirolimus in patients with metastatic breast cancer.Semantic proximity Read ↗

Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.Semantic proximity Read ↗

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.Semantic proximity Read ↗

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.